CN112245518A - 一种治疗粒细胞型白血病的中药组合物 - Google Patents
一种治疗粒细胞型白血病的中药组合物 Download PDFInfo
- Publication number
- CN112245518A CN112245518A CN202011470215.1A CN202011470215A CN112245518A CN 112245518 A CN112245518 A CN 112245518A CN 202011470215 A CN202011470215 A CN 202011470215A CN 112245518 A CN112245518 A CN 112245518A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- treating
- leukemia
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 208000025113 myeloid leukemia Diseases 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims description 13
- 210000003714 granulocyte Anatomy 0.000 claims abstract description 18
- 208000032839 leukemia Diseases 0.000 claims abstract description 18
- 244000306301 Caesalpinia sappan Species 0.000 claims abstract description 7
- 235000015162 Caesalpinia sappan Nutrition 0.000 claims abstract description 7
- 241000233805 Phoenix Species 0.000 claims abstract description 7
- 244000061458 Solanum melongena Species 0.000 claims abstract description 7
- 235000002597 Solanum melongena Nutrition 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 244000281702 Dioscorea villosa Species 0.000 claims abstract description 5
- 241000123865 Gynura bicolor Species 0.000 claims abstract description 5
- 210000000078 claw Anatomy 0.000 claims abstract description 5
- 241000334160 Isatis Species 0.000 claims abstract description 4
- 241000226555 Leontopodium Species 0.000 claims abstract description 3
- 241001080798 Polygala tenuifolia Species 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 241000334154 Isatis tinctoria Species 0.000 claims description 3
- 241000208966 Polygala Species 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims description 2
- 241000282320 Panthera leo Species 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 16
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 5
- 230000006907 apoptotic process Effects 0.000 abstract description 4
- 230000004069 differentiation Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 241000207925 Leonurus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001083548 Anemone Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 235000013757 Juglans Nutrition 0.000 description 1
- 241000758789 Juglans Species 0.000 description 1
- 241001252483 Kalimeris Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000191416 Thevetia Species 0.000 description 1
- 240000001923 Thevetia neriifolia Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗粒细胞型（原性粒和早幼粒细胞、晚幼粒等，下同）白血病的中药，是由下列重量份的原料药组成：黄夹甙0.001～0.002重量份；红背银莲花1.5～3重量份；远志、凤凰爪、苏木4.5～9重量份；萆薢、狮子草、野茄树根、菘蓝叶9～18重量份。本发明可以增强机体免疫功能，杀死粒细胞型白血病细胞、诱导粒细胞型白血病细胞分化和凋亡、防止粒细胞型白血病细胞转移，减轻患者痛苦、提高病人生存质量，提高了粒细胞型白血病患者的治愈率，具有治疗效果显著、无毒副作用等特点。
Description
技术领域
本发明涉及中药的制备领域，特别是涉及一种治疗粒细胞型白血病的中药组合物。
背景技术
粒细胞型（原性粒和早幼粒细胞、晚幼粒等，下同）白血病，是一种影响血液及骨髓的恶性肿瘤，它的特点是产生大量不成熟的白细胞，这些白细胞在骨髓内聚集，抑制骨髓的正常造血；并且能够通过血液在全身扩散，导致病人出现贫血、容易出血、感染及器官浸润等。
传统治疗方法有种种缺陷，化疗药物几乎都是细胞毒性药物，在杀死肿瘤细胞的同时，对人体的正常细胞有一定的毒副作用，尤其是对分裂、增殖、比较快的细胞如骨髓造血细胞、胃肠道粘膜上皮细胞等。化疗会缩短患者生存时间且部分肿瘤对药物不敏感，化疗不可能彻底杀死体内所有粒细胞型白血病细胞，在一定的时间内粒细胞型白血病细胞还会复发或转移。
放射治疗常作为一种辅助治疗或姑息治疗手段。放射治疗在破坏肿瘤的同时，正常组织细胞也会受到一定的损害，超过这一限制剂量就会对组织产生不可逆损害，而且，放射治疗还可能降低机体的免疫力。
发明内容
本发明的目的在于改进已有技术的不足而提供一种治疗粒细胞型白血病的中药组合物，使其可以有效的抵抗粒细胞型白血病细胞、防止粒细胞型白血病细胞转移，提高了粒细胞型白血病患者的治愈率，具有治疗效果显著、无毒副作用等特点。
本发明提供了一种治疗粒细胞型白血病的中药组合物，该中药组合物包括：本发明公开了一种治疗粒细胞型白血病的中药，是由下列重量份的原料药组成：黄夹甙0.001～0.002重量份；红背银莲花1.5～3重量份；远志、凤凰爪、苏木4.5～9重量份；萆薢、狮子草、野茄树根、菘蓝叶9～18重量份。
在一个优选的实施方案中，所述治疗粒细胞型白血病的中药组合物由下列重量份的原料药组成：黄夹甙0.002重量份；红背银莲花3重量份；远志、凤凰爪、苏木9重量份；萆薢、狮子草、野茄树根、菘蓝叶18重量份。
本发明还提供一种治疗粒细胞型白血病的口服制剂，该口服制剂由上述中药组合物制成。
其中，远志：味苦、辛、温。归心、肾、肺经。安神益智，祛痰，消肿。对人慢性粒细胞白血病细胞株表现出明显的细胞毒效应。
菘蓝叶：味苦，寒。归心、胃经。清热解毒，凉血消斑。菘蓝叶对慢性粒细胞白血病患者的细胞兔疫功能有明显的提高，从临床疗效观察，治疗慢性粒细胞性白血病的疗效与马利兰相当，且无明显骨髓抑制作用。对白血病引起的胃肠炎，肺炎有很好疗效。
萆薢：苦，平。入肝、胃、膀胱经。祛风，利湿。
对粒细胞白血病细胞有较强的细胞毒性，在体外会引起人粒细胞白血病细胞株DNA断裂可诱导其细胞凋亡而发挥抗其细胞增殖作用。
凤凰爪：苦，寒。归心、肝、胃、大肠、膀胱经。清热燥湿，杀虫，利尿。凤凰爪碱对慢性粒细胞白血病外周多向造血祖细胞集落产生率有显著的抑制作用，抑制率达76%，可显著地诱导慢性粒细胞白血病细胞向单核巨噬细胞方向分化。
黄花夹竹桃：辛、苦，温。有乳汁和种子大毒。强心，利尿，消肿。黄花夹竹桃提取的黄夹甙口服对人慢性粒细胞白血病细胞有很强杀伤作用。
红背银莲花：辛，热；有毒。归脾经。祛风湿，消痈肿。
对治疗粒细胞白血病细胞增殖有非常强的抑制作用，且药物质量与浓度正相关。
狮子草：苦、辛，寒。清热，解毒，消肿。狮子草水煎提取液对急性粒细胞型白血病及急性单核细胞型白血病患者的血细胞脱氢酶都有较强的抑制作用。
野茄树根：味辛、苦，微温。有毒。止痛，解毒，收敛。
白血病野茄树根水煎服25天后，可使慢性粒细胞型白细胞下降，脾肿大缩小，症状缓解，延长生存期。
苏木：甘、咸，平。归心、肝、脾经。行血祛瘀，消肿止痛。苏木水对人早幼粒白血病细胞、人粒细胞白血病的细胞均有明显的杀伤作用，能明显延长患者的生存时间。
本发明是由中国传统的中草药制成，根据中医辨证论治及现代医学的若干原则，以某些成分确定、功效明晰的天然提取物的有序配伍，组合成了有诱导粒细胞型白血病细胞凋亡与促使其分化的中药。
本发明既有化学治疗之功，又平和无毒，可谓“零毒化疗”。 用药多年来，患者无任何不良反应，跟踪血液检查正常，且疗效不反弹。
本发明可以使各中药成分在发挥其抗癌作用的同时相互协同，相辅相成，可以起到相互促进的作用，既能抑制粒细胞型白血病细胞的增值，又能杀死粒细胞型白血病细胞诱导粒细胞型白血病细胞凋亡，起到治疗粒细胞型白血病的作用，快速帮助患者康复。
本发明能够帮助晚期粒细胞型白血病患者改善症状、减轻痛苦、提高病人生存质量。对于已复发或转移及无法进行放化疗治疗的患者，通过单独服用本配方中药，增强机体免疫功能，诱导粒细胞型白血病细胞分化和凋亡，也可以达到延长病人生命的作用，长期生存，甚至有可能治愈。
本发明所述的中药组合物可用于治疗粒细胞型白血病，具有显著疗效。本发明治疗费用相对低廉，远远低于西医的治疗费用。
本发明的中药组合物原料易得，工艺简单，成本低，效率高，有利于制药企业进行药品生产、质量控制；产品价格低，易于被患者接受。
本发明还提供了一种由上述治疗该病的中药组合物制成的口服制剂，所述口服制剂包括口服液、片剂、胶囊剂、丸剂等，优选剂型为口服液和胶囊剂，一日一剂，分早晚两次服用。
本发明的中药组合物可以制备成多种剂型。例如，将煎煮后的药液杀菌消毒后装袋，制成口服液；或者将煎煮后的药液进行浓缩，烘干后，加入医学上可接收的辅料，然后制成片剂、胶囊剂、丸剂等。
所述医学上可接收的辅料包括淀粉、糊精、羧甲基纤维素钠、聚乙二醇、磷酸氢钙、海藻酸钠、山梨酸钾等。
以上所述，仅是本发明的较佳实施例而已，并非对本发明作任何形式上的限制，本领域技术人员利用上述揭示的技术内容做出些许简单修改、等同变化或修饰，均落在本发明的保护范围内。
Claims (4)
1.一种治疗粒细胞型（原性粒和早幼粒细胞、晚幼粒等，下同）白血病的中药，其特征是由下列重量份的原料药组成：黄夹甙0.001～0.002重量份；红背银莲花1.5～3重量份；远志、凤凰爪、苏木4.5～9重量份；萆薢、狮子草、野茄树根、菘蓝叶9～18重量份。
2.根据权利要求1所述的一种治疗粒细胞型白血病的中药，其特征是由下列重量份的原料药组成：黄夹甙0.002重量份；红背银莲花3重量份；远志、凤凰爪、苏木9重量份；萆薢、狮子草、野茄树根、菘蓝叶18重量份。
3.一种治疗粒细胞型白血病的口服制剂，其特征是由权利要求1或2中任一项所述的中药组合物制成。
4.根据权利要求3所述的一种治疗粒细胞型白血病的口服制剂，其特征是，所述口服制剂包括口服液、片剂、胶囊剂、丸剂，优选口服液和片剂。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010821452 | 2020-08-15 | ||
| CN2020108214521 | 2020-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112245518A true CN112245518A (zh) | 2021-01-22 |
Family
ID=74225781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011470215.1A Pending CN112245518A (zh) | 2020-08-15 | 2020-12-15 | 一种治疗粒细胞型白血病的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112245518A (zh) |
-
2020
- 2020-12-15 CN CN202011470215.1A patent/CN112245518A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| CN112691130A (zh) | 圆叶节节菜及其提取物在用于制备治疗肠胃疾病药物的用途及药物配方 | |
| KR101045025B1 (ko) | 천식 치료 또는 예방용 약학조성물 | |
| JP2014208620A (ja) | 抗肥満剤 | |
| KR100878436B1 (ko) | 금은화 추출물을 포함하는 소화성 궤양 치료 또는 예방용 약학조성물 | |
| CN112245518A (zh) | 一种治疗粒细胞型白血病的中药组合物 | |
| CN113304226A (zh) | 一种治疗肺癌的中药组合物 | |
| CN113368205A (zh) | 一种治疗胃癌的中药组合物 | |
| RU2408383C1 (ru) | Композиция с противоопухолевой и адаптогенной активностью (варианты) и лекарственный препарат на ее основе (варианты) | |
| CN112426486A (zh) | 一种治疗早幼粒细胞白血病的中药组合物 | |
| CN100406026C (zh) | 一种治疗慢性胃炎、胃癌的药物及其制备方法 | |
| CN103948899B (zh) | 一种治疗萎缩性胃炎的藏药 | |
| CN108125237B (zh) | 一种镇咳祛痰抗炎的保健品及其制备工艺 | |
| CN103040975B (zh) | 一种用于护理治疗小儿腹泻的中药组合物 | |
| CN111905034A (zh) | 一种防治非洲猪瘟中药组合物及其制备方法 | |
| CN1231242C (zh) | 一种治疗小儿病毒性肺炎的药物组合物及其制备方法 | |
| CN104189167A (zh) | 一种治疗仔猪腹泻的巴布剂及其制备方法 | |
| CN112426491A (zh) | 一种治疗恶性黑色素瘤的中药组合物 | |
| CN112426475A (zh) | 一种治疗淋巴细胞白血病的中药组合物 | |
| CN111588751A (zh) | 一种治疗急性胃肠炎、痢疾的中药组合物 | |
| CN111759901B (zh) | 一种治疗儿童功能性腹痛的中药组合物及其制备方法 | |
| CN112426469A (zh) | 一种治疗艾氏腹水癌的中药组合物 | |
| CN113648391A (zh) | 一种治疗白血病的中药组合物 | |
| CN112426500A (zh) | 一种治疗宫颈癌的中药组合物 | |
| CN112316071A (zh) | 一种治疗肝癌的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210122 |